Microarray Analysis of Sinus Samples From Patients With and Without Chronic Rhinosinusitis



Status:Active, not recruiting
Conditions:Sinusitis
Therapuetic Areas:Otolaryngology
Healthy:No
Age Range:18 - Any
Updated:11/3/2017
Start Date:October 2007
End Date:September 2018

Use our guide to learn which trials are right for you!

Mucosal biopsies, endoscopically-guided brush samples of mucus, and a saline lavage taken
from the maxillary sinuses of ten CRS patients undergoing sinus surgery are analyzed using
three microarrays in order to detect bacteria, fungi and viruses. Ten control patients with
normal sinuses will have the same samples taken. The hypothesis is that bacterial, fungal,
and viral communities present in the maxillary sinus of patients with CRS are significantly
different from those patients with healthy sinuses, and that microorganisms identified in
patients with or without CRS will differ from previously published data obtained using other
techniques.

Mucosal biopsies, endoscopically-guided brush samples of mucus, and a saline lavage taken
from the maxillary sinuses of ten CRS patients undergoing sinus surgery are analyzed using
three microarrays: 16S rRNA PhyloChip (to detect bacteria), MycoChip (to detect fungi) and
ViroChip (to detect viruses). Ten control patients with normal sinuses, as assessed by CT
scan and a sinusitis-specific survey, will have the same samples taken. The hypothesis is
that bacterial, fungal, and viral communities present in the maxillary sinus of patients with
CRS are significantly different from those patients with healthy sinuses, and that
microorganisms identified in patients with or without CRS will differ from previously
published data obtained using other techniques. Comparing diseased and control flora will
provide insight into the relative contribution of each pathogen to CRS and may guide the
development of future therapies.

Inclusion Criteria (CRS patients):

- History of CRS as defined as symptoms (nasal discharge, nasal obstruction, facial pain
and/or hyposmia) for >12 weeks despite therapy.

- Impaired CRS-specific quality of life (SNOT-20 score >1.5).

- Evidence of sinus disease on a CT scan (Lund MacKay score greater than or equal to
10).

- Patients with positive skin or RAST testing to an inhalant allergen and/or aspirin
hypersensitivity will be included. Evidence of atopy is not required but will be
recorded, along with serum IgE levels, when available.

Inclusion Criteria (Control patients):

- No history of CRS

- SNOT-20 score <1.0

- No evidence of sinus disease on preoperative imaging

Exclusion Criteria:

- Control patients with any evidence of CRS, by history, survey, or imaging criteria
would be excluded.
We found this trial at
1
site
?
mi
from
San Francisco, CA
Click here to add this to my saved trials